MedTrace Logo

Effect of Growth Hormone on Uterine Receptivity in Women With RIF in an Oocyte Donation Program

NCT03237117 · Status: UNKNOWN · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 105

Last updated 2017-08-02

No results posted yet for this study

Summary

105 infertile women are enrolled in the randomized controlled trial: 70 women with a history of RIF with donated oocytes and 35 infertile women undergoing the first oocyte donation attempt. Women receiving donated oocytes are treated with progressively increasing doses of oral estradiol followed by intravaginal progesterone after previous pituitary desensitization with GnRH agonist. 35 RIF patients are treated with GH (GH patients) while the rest 35 RIF patients (non-GH patients) and 35 first-attempt patients (positive control group) are not.

Conditions

  • Female Infertility

Interventions

BIOLOGICAL

Growth Hormone (GH)

to evaluate the effect of GH administration in the donated oocyte recipient program among women with RIF (repeated implantation failure)

Sponsors & Collaborators

  • Universidad de Granada

    collaborator OTHER

  • Competence Centre on Health Technologies

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
51 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-01-01
Primary Completion
2017-12-31
Completion
2017-12-31

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03237117 on ClinicalTrials.gov